The DeLIVER Study

It’s time for a new approach
to type 2 diabetes.

Local research study. One procedure.
No cost to participate.

Each year in the US alone, over 1.4 million people are diagnosed with type 2 diabetes.1 Type 2 diabetes may get worse over time and can lead to serious health complications, such as heart disease, high blood pressure, nerve damage, and blindness.2

If you are trying to control your blood sugar levels, you know how difficult this can be. Daily diabetes medications can initially work well, but often become less effective over time. As the disease progresses, many people need increasing amounts and combinations of medications that can have side effects. Ultimately, this can lead to daily insulin injections and further complications.3

Right now, doctors at select centers in the US are conducting a new research study that may be able to help. The study is evaluating a one-time, minimally-invasive procedure intended to improve blood sugar control without new medications. If you have type 2 diabetes and high blood pressure, we invite you to see if the DeLIVER U.S. Study may be right for you.

About the DeLIVER U.S. Study


Type 2 Diabetes - The Role of Overactive Nerves
People with type 2 diabetes have abnormal levels of sugar, also known as glucose, in their blood. The liver, which both regulates and produces glucose, can be a key contributor to the development and progression of type 2 diabetes. When the liver produces too much glucose, it may be caused by overactive nerves that send information from the brain to the liver.4

 

The iRF Denervation System
The iRF Denervation System is an investigational device designed to permanently disrupt overactive nerves through a one-time, minimally invasive procedure.

The iRF procedure is performed through a small incision in the groin. The iRF catheter is guided to the common hepatic artery leading to the liver. Radiofrequency (heat) energy is delivered from the catheter to the nerves surrounding the artery. This disrupts the overactive nerves leading to the liver. After the procedure is complete, the iRF catheter is removed, leaving nothing behind.

The iRF System is currently being offered through a new clinical research study, called the DeLIVER U.S. Study. If you qualify and choose to join the study, you will receive the iRF procedure and all study-related care at no cost.

Why Participate?

If you have type 2 diabetes and high blood pressure, you may qualify for the DeLIVER U.S. Study. The study is evaluating the iRF Denervation System, an investigational device, designed to improve blood sugar control without new medications. If you qualify and choose to join the study, you will receive:

  • Multiple evaluations of your type 2 diabetes and high blood pressure from a participating doctor
  • The iRF procedure and all study-related care at no cost
  • The opportunity to help advance type 2 diabetes research to potentially benefit others living with type 2 diabetes

See If You Qualify

The DeLIVER U.S. Study is enrolling people ages 22 - 70 who have type 2 diabetes and high blood pressure. To see if you might qualify, and to get connected with your local study center to learn more, please complete the questionnaire below.

  1. www.diabetes.org/resources/statistics/statistics-about-diabetes
  2. www.mayoclinic.org/diseases-conditions/type-2-diabetes
  3. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281:2005.
  4. JARHULT ANN SURG 1979